Largest U.S. standalone medical device maker Medtronic reported a third-quarter profit in-line with analysts’ estimates, as sales across all its units, except the minimally invasive therapies business, grew.
Sales in its cardiac as well as vascular unit which sells defibrillators, pace-makers, heart valves as well as stents jumped 10 percent to $2.8 billion, accounting for nearly 40 percent of its total sales.
The minimally invasive therapies business, which the company acquired as part of its $42.9 billion deal to buy Covidien in 2015, generated sales of $2.04 billion, a 16 percent fall via the year-ago quarter.
Excluding items, Medtronic earned $1.17 per share within the quarter, in-line with analysts’ estimates, according to Thomson Reuters I/B/E/S.
Medtronic, which redomiciled to Ireland through its Covidien deal, said the idea saw a $2.2 billion net charge related to recent modifications within the U.S. tax laws.
The company reported a third-quarter loss of $1.39 billion, or $1.03 per share, within the quarter ended Jan. 26, compared which has a profit of $821 million, or $0.59 per share, a year earlier.
Net sales rose 1.2 percent to $7.37 billion, beating estimates of $7.21 billion.